Study: Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial – The Lancet (link to abstract – $ for full-text)

Source: ACP Journal Club

In this study, patients at high risk of both cardiovascular and gastrointestinal events who required concomitant aspirin and NSAID, celecoxib associated with a proton pump inhibitor led to less recurrent gastrointestinal bleeding when compared to naproxen associated with a proton pump inhibitor (5.6% vs 12.3%).